Adaptation of Hybridization Capture of Chromatin-associated Proteins for Proteomics to Mammalian Cells
June 1st, 2018
5.7K views
This is a method to identify novel DNA-interacting proteins at specific target loci, relying on sequence-specific capture of crosslinked chromatin for subsequent proteomic analyses. No prior knowledge about potential binding proteins, nor cell modifications are required. Initially developed for yeast, the technology has now been adapted for mammalian cells.
Overview
This method identifies novel DNA-interacting proteins at specific target loci through sequence-specific capture of crosslinked chromatin for proteomic analyses. It is adaptable for mammalian cells and does not require prior knowledge of binding proteins.
Key Study Components
Area of Science
- Genomics
- Proteomics
- Cell Biology
Background
- The method is designed to explore genome regulation.
- It addresses how non-coding sequence variants affect gene expression.
- It identifies proteins that bind to DNA at specific loci.
- No genetic manipulation or antibodies are required.
Purpose of Study
- To understand the impact of disease-associated variants on gene regulation.
- To identify DNA-binding proteins without prior knowledge.
- To provide a straightforward method for researchers.
Methods Used
- Designing oligonucleotides based on a text protocol.
- Plating lymphoblastoid cells in RPMI 1640 medium.
- Incubating cells at 37 degrees Celsius with 5% carbon dioxide.
- Measuring cell density using a hemocytometer or automated counter.
Main Results
- The method successfully identifies DNA-interacting proteins.
- It demonstrates the potential to study gene regulation mechanisms.
- It provides a non-invasive approach to proteomic analysis.
- Adaptation for mammalian cells expands its applicability.
Conclusions
- This technique enhances understanding of genome regulation.
- It allows researchers to explore protein-DNA interactions effectively.
- The method's simplicity makes it accessible for various studies.
Frequently Asked Questions
What is the main advantage of this method?
It does not require genetic manipulation or prior knowledge of DNA-binding proteins.
Can this method be used in mammalian cells?
Yes, it has been adapted for use in mammalian cells.
What type of cells can be used in this method?
Lymphoblastoid cells and other cell lines can be used.
What is the incubation condition for the cells?
Cells should be incubated at 37 degrees Celsius with 5% carbon dioxide.
How is cell density measured?
Cell density can be measured using a hemocytometer or an automated cell counter.
Who demonstrates this procedure?
Danu Perumalla, a technician from the laboratory, demonstrates the procedure.
Executive Industry Relevance
HyCCAPP enables unbiased discovery of DNA-protein interactions at specific genomic loci without requiring prior knowledge of binding proteins or genetic manipulation, addressing a key gap in target validation for non-coding disease variants. By adapting the method to mammalian cells, it supports mechanistic de-risking in early discovery by revealing novel regulatory mechanisms linked to pharmacologically relevant pathways. This capability enhances predictive confidence in lead identification and portfolio triage for therapeutics targeting gene regulation mechanisms.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by identifying novel DNA-binding proteins at disease-associated loci.
- Operational Value: Provides an antibody-free, unbiased approach to reduce mechanistic ambiguity in target validation.
- Predictive Value: Supports functional target validation and pathway clarification for de-risking early-stage hypotheses.
Screening & Assay Development
- Assay Readiness: Generates enriched chromatin fractions suitable for downstream proteomic analysis, enabling systematic screening of DNA-interacting proteins.
- Reproducibility: Demonstrates consistent capture yields across replicate experiments using standardized oligonucleotide inputs.
- Scalability: Compatible with various cell lines and adaptable to high-throughput workflows for target engagement profiling.
Translational & Preclinical Research
- Disease Relevance: Facilitates study of how non-coding sequence variants alter protein binding and gene expression in mammalian cells.
- Translational Continuity: Enables follow-up validation using complementary methods like ChIP to map genome-wide binding of identified proteins.
- Risk-Adjusted Advancement: Supports mechanistic de-risking by linking target engagement to functional regulatory outcomes.
Pipeline & Workflow Integration
HyCCAPP fits within the discovery continuum from target hypothesis testing through lead identification, providing mechanistic insights that inform preclinical validation decisions.
- Discovery Biology: Supports hypothesis testing by identifying proteins that bind to specific genomic regions of interest.
- Screening: Delivers quantitative chromatin enrichment outputs that enable comparison of protein binding across experimental conditions.
- Analytics: Generates qPCR-assessable capture yields and specificity metrics to evaluate experimental success and reproducibility.
- Translational Research: Connects to downstream workflows by providing protein candidates for further functional and genomic validation.
- Enterprise Reuse: Establishes a reusable platform for probing diverse genomic loci without reformulating core capture chemistry.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through unbiased identification of novel DNA-protein interactions.
- Operational Value: Standardized workflow with defined lysis, hybridization, and elution steps ensuring reproducibility.
- Strategic Value: Informs go/no-go decisions by reducing biological risk associated with poorly understood regulatory mechanisms.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on mechanistic evidence from direct chromatin proteomics.
Implementation Considerations
- Requires expertise in molecular biology, chromatin handling, and proteomic sample preparation.
- Dependent on access to sonication equipment, magnet-based separation tools, and qPCR systems for yield assessment.
- Necessitates cross-team standardization of oligonucleotide design and hybridization conditions for reproducible results.
- Adaptation across model systems may require optimization of cell culture scale and lysis parameters.
- Practical limitation: Capture efficiency depends on oligonucleotide specificity and chromatin accessibility, necessitating empirical testing per target region.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in HyCCAPP?
Null hypothesis testing helps determine whether observed protein enrichment at a target locus is statistically significant compared to background, ensuring that identified DNA-protein interactions are not due to random binding. This supports confident target validation by distinguishing specific signals from noise in proteomic data.
How does independent variable isolation fit the discovery pipeline in HyCCAPP?
Isolating the target genomic region as the independent variable allows researchers to assess how specific DNA sequences influence protein binding without confounding genetic modifications. This enables precise hypothesis testing in early discovery by linking sequence variation to functional proteomic outcomes.
What quantitative dependent variable measurements enable target engagement assessment in HyCCAPP?
Quantitative measurement of captured DNA yield via qPCR serves as the dependent variable, reflecting the efficiency of chromatin enrichment at the target locus. This metric enables comparison of protein binding across conditions and supports dose-response or variant impact analyses.
Why do replication requirements matter for cross-functional collaboration in HyCCAPP?
Replication ensures that chromatin capture and protein identification results are consistent across experiments, which is essential for building confidence in findings shared between discovery, proteomics, and translational teams. Standardized replication supports reliable data handoff for downstream validation.
What statistical analysis capabilities are required before implementing HyCCAPP in a discovery workflow?
Researchers need the ability to compare capture yields between experimental and control conditions using statistical tests to assess significance. This includes evaluating enrichment over scrambled oligonucleotide controls and technical replicates to confirm target-specific signal.
Chapters in this video
0:04
Title
0:44
Cell Culture
3:13
Lysis and Shearing
4:14
Hybridization Capture
6:14
Evaluation of Capture Yield by qPCR with Primers for the Target Capture Region of Interest
7:12
Results: Hybridization Capture of Chromatin-associated Proteins in Mammalian Cells
8:38
Conclusion
